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Techniques to genetically manipulate the activity of defined neuronal subpopulations have
been useful in elucidating function, however applicability to translational research beyond
transgenic mice is limited. Subtype targeted transgene expression can be achieved
using specific promoters, but often currently available promoters are either too large to
package into many vectors, in particular adeno-associated virus (AAV), or do not drive
expression at levels sufficient to alter behavior. To permit neuron subtype specific gene
expression in wildtype animals, we developed a combinatorial AAV targeting system that
drives, in combination, subtype specific Cre-recombinase expression with a strong but
non-specificCre-conditional transgene.Usingthissystemwedemonstrate that thetyrosine
hydroxylase promoter (TH-Cre-AAV) restricted expression of channelrhodopsin-2 (EF1α-
DIO-ChR2-EYFP-AAV) to the rat ventral tegmental area (VTA), or an activating DREADD
(hSyn-DIO-hM3Dq-mCherry-AAV) to the rat locus coeruleus (LC). High expression levels
were achieved in both regions. Immunohistochemistry (IHC) showed the majority of ChR2+
neurons (>93%) colocalized with TH in the VTA, and optical stimulation evoked striatal
dopamine release. Activation of TH neurons in the LC produced sustained EEG and
behavioral arousal. TH-specific hM3Dq expression in the LC was further compared with:
(1) a Cre construct driven by a strong but non-specific promoter (non-targeting); and (2) a
retrogradely-transported WGA-Cre delivery mechanism (targeting a specific projection).
IHC revealed that the area of c-fos activation after CNO treatment in the LC and peri-LC
neurons appeared proportional to the resulting increase in wakefulness (non-targeted >
targeted > ACC to LC projection restricted). Our dual AAV targeting system effectively
overcomes the large size and weak activity barrier prevalent with many subtype specific
promoters by functionally separating subtype specificity from promoter strength.
Keywords: dual AAV targeting, wild-type, optogenetic, chemogenetic, DREADD, tyrosine hydroxylase (TH), ventral
tegmental area (VTA), locus coeruleus (LC)
Abbreviations: AAV, Adeno-associated virus; ACC, Anterior cingulate cortex; AP, Anterior-posterior; ChR2,
Channelrhodopsin; CMV, Cytomegalovirus; CNO, Clozapine N-oxide; DA, Dopamine; DIO, Double inverted open
reading frame; DREADD, Designer receptor exclusively activated by designer drugs; DV, Dorsal-ventral; EEG,
Electroencephalography; EMG, Electromyography; FSCV, Fast scan cyclic voltammetry; hM3Dq, DREADD derived
from the human muscarinic 3 receptor, activating Gq; hSyn, Human synapsin; LC, Locus coeruleus; ML, Medial-lateral;
NREM, Non-rapid eye movement sleep; REM, Rapid eye movement sleep; TH, Tyrosine Hydroxylase; VTA, Ventral
tegmental area; WGA, Wheat germ agglutinin.
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Introduction
Despite their exceptional value as experimental model systems,
rats and other wild-type species have one substantial drawback:
their genetic tractability as a model organism falls far short
of the mouse. To overcome this, viral vectors have been used
in rats to manipulate CNS function (e.g., through delivery
of genes, antisense or RNAi) in restricted brain regions of
interest. However, viruses indiscriminately transduce most cell
types within the region they are introduced. Since the brain
is highly heterogeneous, there is a clear need to manipulate
neuronal subtypes independently in order to: (1) understand
the genetic basis of neurobiological phenomena; and (2)
selectively target regions and cell groups for therapeutic
purposes. Rat Cre driver lines have been developed and will
provide a similar level of selectivity to mouse models, but
they are not yet common and like transgenic mice they
require a significant investment in time and resources to
maintain. Thus there remains a clear need to pursue other
techniques.
Adeno-associated virus (AAV) has proven to be very effective
for studying neuronal function and behavior. It is long-lived,
highly neurotropic, non-pathogenic and, importantly, it can
drive transgene expression at significantly high levels necessary
to alter neuronal function and produce a behavioral phenotype
(McCown, 2011). However, AAV is relatively small with a limited
packaging capability, often cited as 4.7–5.4 kilobases (Grieger and
Samulski, 2005). Thus AAV cannot be used in targeting strategies
that require large cell type specific promoters. In addition, cell
type specific promoters are usually relatively weak and unable to
drive sufficient levels of expression for experimental purposes.
While a few minimal subtype specific promoters are available,
their use has been limited to just a very few neuronal subtypes
and discrete brain regions (Konadhode et al., 2013; Vazey
and Aston-Jones, 2014). Alternatively, combinatorial strategies
have been designed to express circuit-manipulating constructs
in adult brains by delivering recombinase-dependent viruses
into discrete brain regions of recombinase-expressing transgenic
animals (Tolu et al., 2010; Fenno et al., 2014). Again, this
approach depends on the availability of specific Cre driver
lines, of which there are few for rats. Importantly, many
physiological phenomena and sophisticated behaviors in rats are
strain dependent.
Here we present a new combinatorial dual AAV vector
approach to achieve specificity while maintaining high
expression levels in wildtype animals, namely rats. The first
AAV incorporates the gene of interest in a double-inverted open
(DIO) reading frame, (Figure 1A) driven by a strong neuron
specific or generalized promoter (human synapsin, hSyn or
elongation factor-1 alpha, EF1α, respectively). In the absence of
Cre the gene is retained in an inverse, non-sense orientation.
The second AAV delivers Cre-recombinase under control of
a subtype specific promoter (1b). We hypothesize that only
small amounts of Cre are needed to reorient the transgene for
expression, thus a significantly weaker, but neuronal subtype-
specific promoter—in this case tyrosine hydroxylase (Oh et al.,
2009)—can drive sufficient Cre expression. In combination,
FIGURE 1 | Adeno-associated virus (AAV) transgenes used in this
study. Schematic maps of AAV vector constructs. (A) Effector gene
constructs, ChR2 and hM3Dq and the promoters used to drive high neuronal
expression rates, EF1-α and hSyn, respectively. Note that both effector
molecule sequences are in the DIO position. (B) Maps of the three vector
constructs used to drive expression of Cre-recombinase. Sizes are
approximate and demonstrate that the TH promoter is much larger than either
EF1-α or CMV. (C) Unlocking of the hM3Dq construct from the DIO orientation
to the sense orientation following Cre-mediated recombination.
these AAVs enable expression of a Cre-dependent transgene in a
cell-type (TH+) specific pattern (1c). This approach then allows
the flexibility of using viral vector constructs expressing different
effectors (e.g., excitatory or inhibitory channelrhodopsins,
DREADDS and other genes of interest) with the same promoter-
Cre AAV (e.g., TH-Cre-AAV), or limiting a transgene to
different neuronal subpopulations utilizing a toolbox of verified
promoter-Cre constructs. For example, a single EF1α-DIO-
gene of interest can be combined with a Cre virus driven by
promoters that restrict to glutamatergic neurons in the targeted
brain region (e.g., the CamK2α promoter in the hippocampus,
forebrain or amygdala; Minichiello et al., 1999). Alternatively,
GABAergic neurons may possibly be targeted with a vesicular
GABA transporter (VGAT) or GAD67 promoter (Figure 2).
To validate this system in vivo we have used: (1) a
Cre-conditional channelrhodopsin-2 (ChR2), co-infused with
a TH-Cre-AAV to restrict expression of ChR2 to TH+
neurons of the ventral tegmental area (VTA); and (2) a Cre-
conditional excitatory DREADD, co-infused with a TH-Cre-
AAV to restrict expression of the hM3Dq to TH+ neurons
of the locus coeruleus (LC). We compared the effectiveness
of TH-targeted Cre with a Cre-recombinase driven by a non-
selective, strong cytomegalovirus promoter (CMV-Cre-AAV)
and a Cre-recombinase targeted to the LC via retrograde
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FIGURE 2 | Overview of the dual virus targeting system for targeted
expression of transgenes to specific neuronal subtypes. In this schematic
we present a brain region with three different neuronal subpopulations:
TH-expressing (yellow), GABAergic (purple) and glutamatergic (blue) neurons.
To examine all three subpopulations individually a researcher could obtain or
create an effector (e.g., gene A, excitatory DREADD or ChR2), and combine
with a virus from an existing toolbox of neuron subtype-specific promoter-Cre
viruses. Depending on the Cre virus chosen, a different neuronal population is
targeted. In other experiments, the effector itself can be switched (e.g., gene B),
and thus multiple genetic manipulations can be conducted within one specific
targeted neuronal subpopulation. In this way, the researcher is only required to
create the appropriate DIO-effector construct once, instead of attempting
multiple promoter-effector combinations, which may be of limited value given
variegations in promoter-gene interaction and weak promoter activity.
transport (Gradinaru et al., 2010; WGA-Cre-AAV) from a LC
target area, the anterior cingulate cortex (ACC). Together our
results demonstrate that dual AAV targeting of TH+ neurons
in the VTA and LC in wild-type animals, likely reflecting
dopaminergic or noradrenergic neurons, is effective and the
amount of recruited TH+ neurons appears proportional to the
behavioral effects.
Materials and Methods
Animals
Adult male Sprague Dawley rats (275–300 g; Harlan,
Indianapolis, IN, USA) were individually housed and had
free access to food and water. All animals were housed under
controlled conditions (12 h light/dark cycle, starting at 7:00
A.M.; 100 lux) in an isolated ventilated chamber maintained
at 20–22◦C. All protocols were approved by the Institutional
Animal Care and Use Committees of Beth Israel Deaconess
Medical Center, Harvard Medical School, Wake Forest School of
Medicine and the University at Buffalo.
Genetic Constructs
We initially tested the dual AAV targeting system with a
channelrhodopsin-2 (ChR2) construct for light induced
neuronal firing. This construct expressed ChR2 under the
control of the elongation factor 1 alpha promoter (EF1α-DIO-
ChR2-EYFP-AAV, hereafter ChR2-AAV, a kind gift from K.
Deisseroth), and also included an enhanced yellow fluorescent
protein (EYFP) fusion, which aids in immunohistochemical
determination of ChR2 expression. In addition, we used the
excitatory M3 DREADD (‘‘Designer Receptors Exclusively
Activated by Designer Drugs’’) packaged into the hSyn-
DIO-hM3Dq-mCherry-AAV (hM3Dq-AAV, a kind gift
from B. Roth) virus to test our combinatorial viral vector
approach. Bryan Roth and colleagues used a directed genetic
evolution technique to develop muscarinic receptors that
are insensitive to acetylcholine but highly responsive to the
clozapine metabolite clozapine-N-oxide (CNO; Armbruster
et al., 2007; Nawaratne et al., 2008). These DREADDs have now
been used in various neuronal populations to control neuronal
activity non-invasively (Alexander et al., 2009; Ferguson
et al., 2011). The transgenes in both of these constructs were
packaged in a double-inverted open (DIO) reading frame
(Figure 1).
To obtain neuronal subtype specificity for TH neurons
we used a 2.5 kb segment of the rat TH promoter that
has previously been shown to drive expression predominantly
in TH neurons including in the LC (Oh et al., 2009). The
2.5 kb TH promoter was cloned into the pAAV vector
to create TH-pAAV. The codon optimized Cre recombinase
gene (improved Cre or iCRE) was subsequently inserted 3′
of the TH promoter (TH-Cre-AAV). Another construct used
to compare the subtype-specific expression of TH-Cre-AAV
with non-subtype specific expression was a virus constitutively
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expressing Cre under the control of the CMV promoter
(referred to here as CMV-Cre-AAV to distinguish it from
the TH-Cre-AAV construct). Finally, to achieve trans-synaptic
transport of Cre-recombinase we used a recently described
wheat-germ agglutinin (WGA)-Cre fusion protein (Gradinaru
et al., 2010) in which the WGA portion of the fusion
protein facilitates retrograde transport of Cre to the cell bodies
of anatomically connected neurons. This fusion protein was
expressed under the control of the EF1α promoter (WGA-
Cre-AAV).
AAV Packaging
All constructs were packaged using the standard triple
transfection protocol in HEK-293 cells to create recombinant
pseudotyped AAV2/10 virus (Xiao et al., 1998). AAV2/10
virus is highly neurotrophic, exhibits enhanced spreading
compared to other commonly used serotypes, and has
previously been used by our laboratories to drive high levels
of expression in both extremely small and large brain regions
(Lazarus et al., 2007; Bass et al., 2013; Anaclet et al., 2014;
Fenno et al., 2014). Viruses were titered using quantitative
PCR and were approximately 1012 vector genome copies
per ml.
Study Design
Rats received intracranial injections of different AAVs and in
varying combinations that included: Experiment (1) TH-Cre-
AAV co-injected with ChR2-AAV in the VTA; (2) TH-Cre-
AAV co-injected with the hM3Dq-AAV in the LC; (3) AAV
expressing Cre under the strong constitutively active CMV
promoter (CMV-Cre-AAV), co-injected with hM3Dq-AAV in
the LC; and (4) WGA-Cre-AAV injected into the ACC and
hM3Dq-AAV into the LC.
Surgery
For optogenetics experiments, rats were anesthetized with
ketamine hydrochloride (100 mg/kg, i.p.) and xylazine
hydrochloride (20 mg/kg, i.p.), infused with virus and implanted
with a fiber optic cannula. Two small holes were drilled and
two skull screws were placed in to secure a cement cap. A
third hole was drilled above the right VTA (5.8 AP; 0.7 ML)
and an optic-fluid cannula (OFC; Doric Lenses, Canada) was
implanted (7.3 DV). A total of 240 nl of TH-Cre-AAV + 960 nl
ChR2-AAV were infused over 3 min. The exposed skull was
coated with dental cement secured by skull screws. For DREADD
experiments, under chloral hydrate anesthesia (7% in saline;
350 mg/kg), fine glass pipettes for the intracranial injections of
different AAVs were lowered to a pre-calculated target bilaterally
into the anterior cingulate cortex (ACC; coordinates: 1.25 AP,
±0.5 ML, 1.0 DV) or bi-laterally into the LC (coordinates:
−9.7 AP, ±1.3 ML, 6.4 DV) based on the rat atlas of Paxinos
and Watson (Watson, 1998) and the solution (600 nl of a
mix of equal parts Cre-AAV and hM3Dq-AAV LC bilateral;
900 nl Wga-Cre-AAV ACC bilateral, 300 nl hM3Dq-AAV
LC bilateral; 600 nl of a mix of equal parts TH-Cre-AAV and
hM3Dq-AAV LC bilateral) was injected by an air pressure
system.
Optical Delivery and Fast-Scan Cyclic
Voltammetry
For the evaluation of changes in extracellular dopamine
concentrations in response to optical stimulation of dopamine
cell bodies, rats (n = 5) were anesthetized with urethane (1.5
g/kg, i.p.) and placed in a stereotaxic frame. The cement cap was
removed and a hole for a carbon fiber electrode (∼100 µm in
length, 6 µm in diameter) insertion was drilled (from bregma:
anterior-posterior, 1.2mm; lateral, 2mm). AnAg/AgCl reference
electrode was implanted in the contralateral hemisphere and a
carbon fiber electrode was positioned in the nucleus accumbens
core (dorsal-ventral, 7.2 mm). The optical fiber (200 µm in
diameter), used for optical activation of ChR2 expressing cells,
was positioned at the level of the dopamine cell body region
300µmabove the virus injection point (unilateral). The reference
and carbon fiber electrodes were connected to a voltammetric
amplifier (UNC Electronics Design Facility, Chapel Hill, NC,
USA) and voltammetric recordings were made at the carbon
fiber electrode every 100 ms by applying a triangular waveform
(−0.4 to +1.3 V, 300 V/s). Light evoked dopamine release was
identified by the background-subtracted cyclic voltammogram.
Carbon fiber microelectrodes were calibrated in vitro with
known concentrations of dopamine (2–5 µM). To analyze
dopamine release and uptake parameters, light-evoked changes
in extracellular dopamine were fit using the equation:
d [DA] /dt = ((f ) [DA]p − (Vmax/ ({Km/[DA]) + 1)
where f is the stimulation frequency (Hz), [DA]p is the
concentration of dopamine released per light pulse, andVmax and
Km are Michaelis-Menten rate constants for dopamine uptake
(Garris and Rebec, 2002; Phillips et al., 2003; Oleson et al., 2009;
Pattison et al., 2011).
The optical stimulation setup was reported in previous work
(Bass et al., 2010) and consisted of a laser at wavelength 473
nm (Beijing Viasho Technology Co., Ltd., Beijing, China) with
a maximum output of 100 mW. The laser was modulated using
the TTL input control port on the laser power supply via a
USB Data Acquisition unit (National Instruments 6221-USB).
The data acquisition unit was controlled by a desktop computer
using LabVIEW software (National Instruments). The software
allowed us to control the frequency of the square pulses, the total
number of pulses in one data stream, and the width of each pulse.
The laser power output was measured using a commercial power
meter (Newport Model 1815C).
EEG/EMG Recording and Sleep Analysis for
DREADD Experiments
After animals were anesthetized with chloral hydrate and
injections were performed as above, the skulls were exposed.
Four EEG screw electrodes were implanted into the frontal (two)
and parietal bones (two) of each side of the skull, and two
flexible EMG wire electrodes were placed into the neck muscles.
The free ends of the leads were fitted into a socket that was
attached to the skull with dental cement. At least 2 weeks after
surgery, the sockets were connected via flexible recording cables
and a commutator to an amplifier (A-M Systems model 3600,
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Carlsborg, WA, USA) and computer, and signals were digitized
using a Dell PC running the Sleep Sign recording system (Kissei
Comtec, Irvine, CA, USA). The EEG/EMG was recorded at the
end of the second week after surgery, for 48 h. Injections of
CNO (0.3 mg/kg) or saline were performed at ZT 5, 24 h into
this continuous recording period in a cross-over design (animals
received either saline or CNO first), and injections were at least
1 week apart from one another to allow sufficient time for CNO
washout and recovery. The cages were placed in such a way that
animals receiving the same treatment were located next to one
another so that the CNO-injected rat did not keep the saline-
injected rat awake. The only exception to this were the sham
virus, CNO injected animals in Figure 7D.
Wake-sleep states were automatically scored and manually
checked in 4 s epochs on the digitized EEG/EMG. Wakefulness
was identified by the presence of a desynchronized EEG
and phasic EMG activity. Additionally, wakefulness was
distinguished from sleep states by use of video monitoring.
Nonrapid eye movement (NREM) sleep consisted of a high
amplitude slow wave EEG together with a low EMG tone relative
to wake. REM sleep was identified by the presence of regular
theta EEG activity coupled with low EMG tone relative to NREM
sleep. The amount of time spent in wake, NREM sleep, and
REM sleep was determined for each 60 min period and treatment
groups were compared using the student’s t-test performed in
Microsoft Excel.
Immunohistochemistry (IHC)
Animals were deeply anesthetized with isoflurane and then
perfused with 50 ml saline followed by 500 ml of 10% formalin
through the heart. The brains were removed, postfixed for
2 h in 10% formalin, and then equilibrated in 20% sucrose
in PBS containing azide overnight. The brains were sectioned
on a freezing microtome at 40 µm into four series. Sections
were washed in 0.1 M PBS, pH 7.4 (two changes), and
then incubated in the primary antiserum for 1 day at room
temperature. For c-Fos, we used a rabbit polyclonal antiserum
(AB5; 1:50,000; Oncogene Sciences, Cambridge, MA, USA)
against residues 4–17 from human c-Fos. This antiserum stains
only the nuclei of neurons based on recent activity patterns
(Gaus et al., 2002; Lu et al., 2002). For Cre, we used a rabbit
polyclonal antiserum (Novagen, lot #D00132036, catalog #69050,
1:10,000). Sections were then washed in PBS and incubated
in biotinylated secondary antiserum (1:1000 in PBS) for 1 h,
washed in PBS, and incubated in avidin-biotin-horseradish
peroxidase conjugate (Vector Laboratories) for 1 h. Sections
were then washed again and incubated in a 0.06% solution
of 3, 3-diaminobenzidine tetrahydrochloride (DAB; Sigma, St.
Louis, MO, USA) plus 0.02% H2O2. The sections were stained
brown with DAB only or black by adding 0.05% cobalt chloride
and 0.01% nickel ammonium sulfate to the DAB solution. For
double immunofluorescence, sections were rinsed in PBS for
5 min and again in PBS + 0.5% triton X-100 three times
for 10 min. Sections were incubated with primary antibodies
overnight at 4◦C. Primary antibodies consisted of a mouse
anti-tyrosine hydroxylase (ImmunoStar #22941, 1:4000) and a
rabbit anti-GFP (Invitrogen #A6455, 1:2000) diluted in PBS +
0.3% triton X-100. For single DsRed immunofluorescence, we
used a rabbit polyclonal antiserum (632496; 1:10,000; Clontech
Laboratories, Inc., Mountain View, CA, USA). The antibody
was raised against the full-length DsRed-Express protein and
recognizes wt DsRed and its variants (Yang et al., 2013). The
next day the sections were rinsed three times for 10 min
each in PBS and then incubated with secondary antibodies
consisting of Alexa 555 donkey anti-mouse (Invitrogen #A31570,
1:4000) and Alexa 488 goat anti-rabbit (Invitrogen #A11034,
1:2000) for the double immunofluorescence experiments and
in red fluorescent Cy3 conjugated donkey anti rabbit (1:10,000;
103422; Jackson ImmunoResearch, West Grove, PA, USA)
for 2 h at room temperature. Sections were rinsed again
in PBS three times for 10 min, mounted on slides and
coverslipped using Prolong Gold media. Slides were visualized
on a Zeiss Axio Observer Confocal microscope. For studies
examining colocalization of TH+ and ChR2-EYFP+ neurons, we
performed immunohistochemistry (IHC) on sections collected
from animals injected with the TH-Cre-AAV + ChR2-AAV
(n = 4). Z-stacks (approximately 35–40, 1.140 µm optical slices)
from several fields in the VTA were collected and examined
using the Zeiss Zen software. ChR2+ cell bodies were carefully
examined in each z-stack to determine if a TH signal was also
present.
Results
Functional Targeting of ChR2 Receptors to TH
Neurons of the VTA
We co-injected TH-Cre-AAV and ChR2-AAV into the VTA
and these animals demonstrated highly specific ChR2 expression
(Figures 3A–F) in TH+ neurons. Several sections from different
subjects were carefully examined to determine the degree of
colocalization between TH and ChR2. A total of 427 ChR2+ cells
were counted, of which 399 were determined to also express
TH, while 28 did not, resulting in approximately 93.4% of
colocalization. In Figure 3G the mean % ChR2+ neurons that
were also TH+ or TH- is represented. We then employed in vivo
fast-scan cyclic voltammetry (FSCV) to determine if the level of
ChR2 expression achieved in the VTA is sufficient for optical
stimulation of dopamine release in the rat nucleus accumbens.
Figures 4A,B demonstrates dopamine efflux, triggered by blue-
light stimulation of the VTA (50 Hz, 50 flashes with 4-ms flash
length, 3 mW). Notably, dopamine release was restricted to the
ventral striatum and largely absent in the dorsal striatum, which
receives dopaminergic inputs primarily from the substantia
nigra. The rising fraction of accumbal dopamine efflux was time-
locked to the 1-s VTA optical stimulation (Figure 4A), whereas
dopamine concentration rapidly declined immediately at the
end of the stimulation due to the reuptake mechanism. The
magnitudes of dopamine uptake parameters, including maximal
velocity of dopamine reuptake rate or Vmax and apparent Km
(Michaelis-Menten constant) were similar to those previously
found for the rat nucleus accumbens core using FSCV in
vivo (Phillips et al., 2003; Jones et al., 2006; Oleson et al.,
2009; Pattison et al., 2011, 2012). Vmax values were between
1.74 and 3.37 µM/s, when Km was set between 0.16 and
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FIGURE 3 | Dual ventral tegmental area (VTA) injection of TH-Cre-AAV
and ChR2-AAV. Immunofluorescence of (C,F) ChR2 expression (green). (B,E)
TH expression (Red). (A,D) Merged image of band (C) and (B), and (E) and (F),
respectively. Note ChR2 expression is limited to TH-expressing neurons, with all
ChR2+ neurons also demonstrating TH (arrows), while some TH+ neurons are
either not expressing ChR2 or doing so at levels below detection limit of this
experiment. (G) Quantification of TH/ChR2 colocalization. ChR2+ neurons were
identified as either TH+ or TH- (n = 4, total of 427 cells).
0.2 µM (n = 5). The responsiveness of dopamine release to
different frequencies (from 10 to 50 Hz, 1 s total duration)
also was evaluated. The magnitudes of light-evoked dopamine
release were frequency dependent (F(4,6) = 9.085, p < 0.0001,
n = 5; one-way ANOVA). The maximal increase in dopamine
release was observed when ChR2 expressing dopamine neurons
of the VTA were stimulated at the 40 Hz frequency. The
averaged values of dopamine release were 27.2 ± 13.8 nM
for 10 Hz, 55.9 ± 10.4 nM for 20 Hz, 74.6 ± 19.3 nM for
30 Hz, 95.6 ± 27.4 nM for 40 Hz and 100.8 ± 30.7 nM
for 50 Hz stimulation (Figure 4C). This exclusive frequency
dependence is likely based on the biological properties of
the ChR2 proteins. According to electrophysiological studies,
many cells cannot follow ChR2-driven spiking above the 40 Hz
range in sustained trains (Lin et al., 2009; Gunaydin et al.,
2010).
Functional Targeting of hM3Dq Receptors in TH
Neurons of the LC
To examine the specificity of expression in another brain
region rich in TH-positive neurons, as well as to verify the
combinatorial viral vector strategy with another commonly
used neuromodulation technique, we injected the LC with
a combination of TH-Cre-AAV and hM3Dq-AAV. hM3Dq
receptor expression was largely restricted to LC neurons
(Figures 5A–H, 6A), although sparse hM3Dq+ cells were
consistently observed in the medial and lateral parabrachial (PB)
nucleus (evident in Figures 5B,C). Given that TH expression has
been previously reported in the PB (Milner et al., 1986), it appears
that the TH promoter used here is driving true eutopic expression
of Cre in this brain region. On the basis of previous work (Gompf
et al., 2010), we hypothesized that administration of the M3
ligand (CNO) would activate the TH+ neurons in the LC and
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FIGURE 4 | Optogenetic stimulation of TH+ VTA neurons. (A)
Dopamine changes detected by fast-scan cyclic voltammetry (FSCV) in
the striatum of a representative anesthetized rat in response to optical
stimulation (50 Hz, 50 pulses) of the middle brain. Top graphs show the
background-subtracted voltammogram obtained at the end of the
stimulation, which demonstrate the characteristic oxidation and reduction
peak potentials (∼ +0.6 V and ∼ −0.2 V, respectively) that identify
dopamine. Bottom traces show the concentration-time plots of
optically-evoked dopamine release measured in real time (left from dorsal
striatum, right from ventral striatum, blue line indicates time of light pulse).
(B) Standard two dimensional color plot which topographically depicts the
voltammetric data with time on the x-axis, applied scan potential on the
y-axis and background-subtracted faradaic current shown in the z-axis in
pseudo-color. Dopamine can be seen during stimulation at the signature
0.65 V (oxidation peak encoded as green). (C) Magnitude of light evoked
dopamine release is frequency dependent.
produce sustained behavioral and electrographic arousal. Bolus
agonist administration (CNO, ip, 0.3 mg/kg) at ZT 5 produced
robust c-Fos expression in the LC, but not in adjacent areas of
the pontine tegmentum (Figure 6B). A concomitant high level of
c-Fos expression was observed throughout the cortex, including
the ACC (Figure 6C). By contrast, very little c-Fos expression was
evident in the LC or ACC following CNO injections in control
rats (Figure 6D). A marked increase in EEG and behavioral
wake was also observed over the 6-h post-injection recording
period (81.6 ± 7.4% vs. 24.1 ± 1.4% waking following saline
injections, p = 0.0001, n = 5; Figure 6E). The power spectra
indicated a normal EEG following CNO injections. Though a
slight elevation in power in the theta band (5–7 Hz) can be
seen in this figure, it is not statistically significant (p = 0.09;
Figure 6F).
Combinatorial Viral Vectors Lacking Subtype
Specificity
LC directed co-injections of viruses constitutively expressing
Cre (CMV-Cre-AAV) and hM3Dq-AAV were performed to
provide a comparison to TH-targeted hM3Dq. CMV-Cre and
hM3Dq-AAV co-infusions resulted in expression of hM3Dq
across vast portions of the pontine tegmentum, including most
of the lateral and medial PB nucleus (lPB, mPB, Figure 7A),
LC and the pre- and sub-coeruleus (Sub-LC, Figure 7A). CNO
(0.3 mg/kg) administration elicited a large waking response (ZT
5–11: 88.5 ± 5.3% vs. 28.0 ± 12.6% following saline injections,
p = 0.001, n = 3, Figure 7D) and concomitant widespread
c-Fos expression across the pons and cortex (Figures 7B,C).
CNO had little to no effect on animals not injected with viral
vectors (Figure 7D). There was a decrease in the wakefulness
immediately following the CNO infusion in sham virus injected
animals, however this is likely an artifact, as we and several other
groups have not observed significant changes in behavior after
CNO treatment across multiple studies. Neither the behavioral
responses nor the c-Fos expression could be attributed to a single
brain region or cell type due to the widespread pontine hM3Dq
expression. We also attempted to limit expression to a particular
LC projection using a previously described method of retrograde
transport of Cre from target regions (Gradinaru et al., 2010).
Infusion of WGA-Cre-AAV into the ACC and hM3Dq-AAV
into the LC resulted in robust Cre expression in both the ACC
(Figure 7E) and the LC (Figure 7F), indicating successful
WGA-mediated Cre transport. Following CNO injection, rats
maintained 86.4 ± 8.7% and 61.8 ± 12.3% wakefulness for the
first 2 and 4 h, respectively compared to 22.4 ± 5.8% following
saline (Figure 7H), and a modest c-Fos expression was observed
in the LC following CNO injections (Figure 7G). The smaller
effect on wakefulness produced by CNO in this experiment
is proportional to activation of only a subset of LC neurons
Frontiers in Behavioral Neuroscience | www.frontiersin.org 7 July 2015 | Volume 9 | Article 152
Gompf et al. Dual AAVs targeting neuronal subtypes
FIGURE 5 | hM3Dq receptor expression following locus coeruleus (LC)
coinjections of TH-Cre-AAV and hM3Dq-AAV. (A–D) hM3Dq expression as
visualized by DS-Red immunofluorescence, and (E–H) mCherry native
fluorescence indicating hM3Dq receptor expression. The approximate area of
the LC is outlined in white in (A–D) to illustrate expression primarily restricted to
LC neurons.
FIGURE 6 | Dual LC injection of TH-Cre-AAV and hM3Dq-AAV.
(A) hM3Dq expression is limited to LC neurons. (B–D) Following CNO
injections, c-Fos expression markedly increased in the LC (B) as well as
the entire neocortex, including the ACC (C), which was not evident in LC
or cortex of animals lacking hM3Dq receptors (D). (E) CNO induced
wakefulness for most of the 6 h period following injection (blue line)
compared to the normal amount of wakefulness observed following saline
injection (red line). (F) Power spectral analysis revealed normal wake EEG
signatures following CNO injection compared to saline (blue and red lines,
respectively).
projecting to the ACC (Chandler et al., 2014). C-Fos was not
quantified in our study.
Discussion
Using our dual combinatorial viral vector-based system
we demonstrate, first, robust expression of two different
transgenes, ChR2 and, hM3Dq in two different TH+ neuronal
populations, the rat VTA and LC, respectively. Secondly,
we demonstrate the ability to robustly alter neurochemical
and behavioral outcomes based on these subtype specific
alterations. Namely, we optically induced dopamine release in
the nucleus accumbens, without any effect on dopamine release
in the dorsal striatum. In addition, we observed a sustained
increase in waking following chemogenetic activation of LC
neurons.
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FIGURE 7 | Dual injections to either the LC or an LC projection.
(A) Dual injection of CMV-Cre-AAV and hM3Dq-AAV into the LC results in
widespread expression of hM3Dq throughout the pons. (B,C) Widespread
c-Fos expression throughout the pons (B) as well as the cortex (e.g.,
ACC, (C) was observed following CNO administration. (D) Wakefulness is
increased in animals receiving this dual injection following CNO
administration (blue line), whereas neither saline in these animals (red line)
nor CNO injections in animals that did not receive viral injections (dashed
gray line) produce prolonged wakefulness. (E,F) WGA-Cre-AAV injection
into the ACC results in Cre expression in the ACC (E), as well as
transport of Cre to the LC (F), where the AAV-hM3Dq vector was
injected. (G) cFos expression is lower in these animals than in animals
expressing hM3Dq throughout the pons (B,C). Wakefulness (H) in these
animals is greater following CNO injection (blue line) than saline (red line).
Dual AAV targeting of ChR2 to TH+ neurons in the
VTA produced an expression pattern consistent with TH+
neurons in the midbrain, as subsequent optical stimulation of
the VTA resulted in the release of dopamine in the nucleus
accumbens, but not in the dorsal striatum. This is consistent
with the known innervation pattern of the striatum by midbrain
dopaminergic neurons, in which the VTA projects primarily to
the ventral portion of the striatum, while the substantia nigra
projects primarily to the dorsal striatum. These neurochemical
data strongly suggest that dual AAV targeting using TH-Cre
can restrict expression to the VTA dopaminergic neurons in
wildtype rats.
The observation that TH-Cre activated hM3Dq expression
in the LC caused CNO-mediated wakefulness of such a
long duration (6 h) is indicative of strong phasic activation
of LC neurons. The LC has two different types of firing
patterns: constant, ∼3 Hz ‘‘phasic’’ activity and intermittent,
∼10 Hz ‘‘tonic’’ impulse activity (Aston-Jones and Bloom,
1981), that have been correlated to different behavioral
states (Aston-Jones and Cohen, 2005). Optogenetics has
shown that phasic activation of LC neurons is capable of
maintaining wakefulness in mice for up to 5 h whereas
tonic LC activation promotes wakefulness for no more
than an hour (Carter et al., 2010). Our results would
therefore be consistent with CNO-driven excitation of TH+
neurons in the LC eliciting phasic firing patterns. Further
studies should address whether hM3Dq receptors activate LC
neurons phasically or tonically, and establish how sustained vs.
acute activation (e.g., chemogenetic vs. optogenetic) promotes
wakefulness.
We have also previously demonstrated in the rat that
reciprocal innervation between the ACC and the LC provides
the necessary circuitry to maintain wakefulness under novel
environmental stimuli (Gompf et al., 2010). We therefore
exploited these previous findings to demonstrate efficacy of
a retrograde transport system for achieving projection-specific
activation of LC neurons. We found that WGA-Cre transport
from the ACC promoted expression of hM3Dq in ipsilateral LC
neurons, although the number of hM3Dq-expressing neurons
was far fewer (∼60% less) than in those animals where AAV-
TH-Cre was co-injected with hM3Dq-AAV into the LC, possibly
because not all LC neurons project to the ACC (Chandler
et al., 2014). We would note that while WGA-mediated Cre
transport (Gradinaru et al., 2010) was chosen in this study to
target projection-specific neurons, similar strategies have been
employed using the retrograde transducing Canine Adenovirus
2 expressing Cre (Gore et al., 2013; Boender et al., 2014). Though
both of these approaches are important in dissecting specific
circuits, they are likely insufficient to target all neurons of a
similar phenotype within a region.
To date, the use of Cre viruses, including lentiviral vectors
(Tolu et al., 2010), have primarily occurred in conjunction
with transgenic mice (Lazarus et al., 2007; Bass et al., 2013;
Anaclet et al., 2014; Fenno et al., 2014), leaving a gap
in our ability to generalize models across multiple species
and limiting many scientists from conducting research using
the most appropriate or translational species. For example,
primates are enormously important in studies of behavior
and human disease etiology, but we cannot easily manipulate
their genetics. Currently a great deal of effort and money
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is being spent to generate transgenic rats and primates,
despite relatively limited success. One notable exception is the
recently generated TH-Cre rat (Brown et al., 2013), which is
widely available. While these endeavors are worthwhile, the
technical constraints of transgenic approaches put them out
of reach for many researchers. Our approach bridges a gap
in the ability to generalize models across multiple species by
providing a relatively flexible system to generate targeted genetic
manipulations to specific brain regions, pathways, and neuronal
subtypes without having to produce and maintain transgenic
animals. Genetic manipulations can be incorporated into existing
wildtype models avoiding breeding costs and issues such as strain
variations and developmental compensation. This flexibility may
be advantageous as newer generation constructs are produced,
such as the recently described INTRSECT system that uses
multiple recombinases (e.g., Cre and Dre) in combination
with expression vectors containing ‘‘intronic recombinase sites
enabling combinatorial targeting’’ (Fenno et al., 2014). For
instance, recent evidence suggests that in transgenic TH-Cre
mice effector gene expression is not limited to dopaminergic
neurons (Lammel et al., 2015; Stuber et al., 2015). If similar
observations are found using the TH-Cre approach described
here, multiple combinatorial viral vectors could potentially be
used to limit expression specifically to dopaminergic VTA
neurons. Additionally, AAV dual vector targeting should permit
neuronal subtype specific restriction in primates, thus greatly
increasing the number of potential therapeutic targets in humans
and allowing for novel non-human primate models of human
disease.
Our dual AAV targeting approach may have additional
benefits over a single virus using a subtype specific promoter.
First, there are limited minimal promoters available that can
sufficiently drive subtype specific expression from a single virus,
such as the PRSx8 promoter, which has been used to limit
DREADD expression to noradrenergic neurons in the LC (Vazey
and Aston-Jones, 2014). In addition, it is possible that a single
virus will have unintended effects due to regulatory elements
in the subtype specific promoter. For example, TH is known
to express in a circadian manner (Sleipness et al., 2007; Sidor
et al., 2015), and thus expression driven directly from the TH
promoter may result in variations in transgene expression with
time of day, depending on whether the minimal promoter still
retains circadian controlled regulatory elements. Such regulatory
influences would be avoided by our combinatorial system where
transgene levels are determined by a generalized promoter.
While we have initially focused on establishing a toolbox
for basic research experiments, our combinatorial AAV dual
vector approach also has the potential to transform gene
therapy application in the CNS. For years scientists have been
using viral vectors to manipulate the genetics of neurons in
primates, including humans, but have generally not pursued
subtype specificity, rather choosing to limit the transgene to
a specific brain region by controlling the infusion location. In
theory, our approach should allow for true subtype specific
targeting in primates. We are currently creating targeted
non-human primate models of human diseases using AAV
dual vector targeting. These models will allow us to test
the translational potential of targeted gene delivery for more
highly targeted gene therapy applications in humans, while
also providing new non-human primate models of human
disease for use in biological and pharmacological intervention
studies.
The most pronounced limitation of the current iteration of
dual AAV targeting is the lack of verified promoters that are
active in wildtype species. In our study we used a previously
verified rat TH promoter (Oh et al., 2009), whereas the
dopamine beta-hydroxylase (PRSx8) promoter appears to also
be successful in targeting noradrenergic neurons (Bruinstroop
et al., 2012; Vazey and Aston-Jones, 2014). Going forward,
and to improve the flexibility of the system, we will need to
expand the toolbox by creating a multitude of subtype specific
Cre viruses. To reach full utility, the relative specificity of each
targeting Cre virus will need to be assessed individually in
different brain regions and across multiple species. It should
be noted that there are likely multiple factors that influence
viral mediated subtype specificity including the size/composition
of the promoter, the AAV serotype, virus titer, purification
method and brain region injected. For example, while a VGLUT2
promoter may be able to target glutamatergic neurons in most
brain regions, potentially it would also restrict expression to
a subset of DAergic neurons in the VTA that also express
VGLUT2 and co-release glutamate. Ultimately a library of
subtype specific Cre viruses could be created, fully characterized
in specific brain regions/species, and made available to the
research community.
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